Introduction {#Sec1}
============

Severe hypoglycemia is an extremely dangerous event \[[@CR1], [@CR2]\]. Several studies have suggested that hypoglycemia in patients with diabetes is associated with increased cardiovascular events and death \[[@CR3]--[@CR5]\]. Moreover, some reports have indicated that hypoglycemia might also be associated with a higher mortality in patients with critical illness \[[@CR6]--[@CR8]\]. However, whether iatrogenic hypoglycemia caused by glucose-lowering agents is associated with increased mortality or whether the underlying diseases causing the hypoglycemia are associated with the high mortality has been unclear and controversial.

Although hypoglycemia in patients with diabetes is mostly iatrogenic and is mainly caused by glucose-lowering agents, such as insulin and sulfonylureas, hypoglycemia in patients without diabetes can be caused by many factors including malnutrition, alcohol abuse, hepatic failure, and sepsis \[[@CR9]\]. A recent study has suggested that severe hypoglycemia in critically ill patients who are not receiving insulin treatment might be associated with increased mortality \[[@CR8]\], and another study has shown that hypoglycemia at the time of hospital admission was associated with in-hospital mortality in patients with sepsis \[[@CR10]\]. However, a systematic study investigating predictors of death in non-diabetic patients with non-iatrogenic hypoglycemia has not been previously performed. The present study examined the clinical conditions and predictors of death in non-diabetic patients with pre-hospital severe hypoglycemia.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

We conducted a retrospective cohort study of non-diabetic patients who had been transported by ambulance and were diagnosed as having severe hypoglycemia at the National Center for Global Health and Medicine Hospital in Tokyo, Japan, between January 1, 2006, and March 31, 2012. Severe hypoglycemia was defined as the presence of any hypoglycemic symptoms that could not be resolved by the patients themselves and that required the medical assistance of another person after visiting the emergency room by ambulance \[[@CR11]\]. Blood glucose levels were mainly measured at a central laboratory (78 %, 411/529), although some were measured using a blood glucose meter (22 %, 118/529). All blood glucose levels of \<20 mg/dL were checked at a central laboratory. In one patient, the blood glucose level was not measured prior to treatment. We preferentially referred to the blood glucose data measured at a central laboratory. We assessed the patients' characteristics, general conditions, and electrocardiograms upon arrival, as well as any complications with severe hypoglycemia and the clinical outcomes. At least two specialists in both diabetology and internal medicine independently reviewed all the data, including the clinical records, laboratory data, and electrocardiograms. Disagreements between the reviewers were resolved by a third internist. Diabetes was confirmed when the patient had been previously diagnosed as having diabetes or was being treated with antidiabetic medicines, and non-diabetic patients were defined as those without diabetes. Patients with cardiopulmonary arrest upon arrival were excluded from this study. We analyzed the data using only the latest hospital visit for each individual. All the eligible patients in this study were followed up for 90 days after severe hypoglycemia. This study was approved by the institutional review board of the National Center for Global Health and Medicine Hospital.

Clinical conditions {#Sec4}
-------------------

We assessed the consciousness level and the vital signs of all the study patients. The consciousness level during severe hypoglycemia was evaluated using the Glasgow Coma Scale (GCS) score \[[@CR12]\]. The GCS score is composed of three parameters: best eye response between 1 and 4, best verbal response between 1 and 5, and best motor response between 1 and 6. The GCS score can range from 3 to 15, with 3 being the worst possible score and 15 being the best possible score. The body temperature upon arrival was measured at the rectum, axilla, and/or tympanic membrane, and we preferentially referred to the rectal temperature. Mild hypothermia was defined as a body temperature \<35 °C, and moderate to severe hypothermia was defined as \<32 °C \[[@CR13]\]. Blood pressure was measured upon arrival. Severe hypertension was defined as a systolic blood pressure ≥180 mmHg and/or a diastolic blood pressure ≥120 mmHg \[[@CR14]\]. Newly diagnosed diseases during episodes of severe hypoglycemia were assessed using the medical records, laboratory data, electrocardiograms, and radiological images. Cardiovascular events were defined as coronary heart disease requiring treatment with revascularization or stroke confirmed by radiological images. Sepsis was defined as systemic inflammatory response syndrome in response to infection. Systemic inflammatory response syndrome was regarded as the presence of two or more of the following criteria: body temperature \>38 or \<36 °C, heart rate \>90 beats per minute, respiratory rate \>20 breaths per minute, and white blood cell \>12,000 per mm^3^. The corrected QT interval (QTc) was calculated using Bazett's formula: QTc = QT interval ÷ square root of the RR interval. A QTc ≥0.44 s was considered to indicate abnormal prolongation, and those ≥0.50 s were considered to be highly abnormal \[[@CR15], [@CR16]\].

Statistical methods {#Sec5}
-------------------

Patients were initially categorized into the diabetes (DM) or non-diabetes (non-DM) group. Data were presented as the number (%), the mean with standard deviation (SD), or the median with the lower and upper ends of the interquartile range (IQR). Continuous variables were compared using *t* tests or Wilcoxon rank-sum tests. Categorical variables were compared using chi-squared tests or Fisher's exact tests. To analyze the GCS score, body temperature, and blood pressure upon arrival, the subjects were divided into two groups according to a cut-off blood glucose level of 40 mg/dL (to convert blood glucose to mmol/L, multiply by 0.0555), which approximated the overall mean value. Cox proportional hazards models were used to identify risk factors associated with death in non-diabetic patients with severe hypoglycemia. The candidate variables included in this model were age, sex, preexisting diseases, QT prolongation, coexisting sepsis, and blood glucose levels. We performed univariate analyses to determine the magnitude of unadjusted associations and subsequently performed multivariate analyses using the variables that were deemed significant in the univariate analyses. Kaplan--Meier analyses were used to assess mortality within 90 days after severe hypoglycemic events, and groups were compared using the log-rank test. *P* values \<0.05 according to a two-sided test were considered statistically significant for all the tests. All the analyses were performed using Stata software, version 11.1 (Stata Corp, College Station, TX, USA).

Results {#Sec6}
=======

A total of 59,602 consecutive cases that visited the emergency room by ambulance were screened, and 530 patients with severe hypoglycemia met the criteria for inclusion in this study (Fig. [1](#Fig1){ref-type="fig"}). The clinical characteristics of this study population upon arrival are presented in Table [1](#Tab1){ref-type="table"}. In the DM group, the numbers (%) of type 1 diabetes, type 2 diabetes, and other diabetes were 63 (17.2 %), 293 (79.8 %), and 11 (3.0 %), respectively. In the non-DM (*n* = 163) and DM (*n* = 367) groups, the mean ± SD blood glucose levels were 42.9 ± 23.2 and 33.7 ± 15.7 mg/dL, respectively (*P* \< 0.001). Patient age and sex were not significantly different between the non-DM and DM groups. The prevalence of known cardiovascular disease and preexisting hypertension in the DM group was significantly higher, and the estimated GFR in the DM group was significantly lower than that in the non-DM group. The patients in the non-DM group had a broad range of causes of severe hypoglycemia, with the major ones being malnutrition, alcohol abuse, post-gastrectomy, and infection. Meanwhile, almost all the patients of severe hypoglycemia in the DM group were caused by glucose-lowering medications, and the causes of severe hypoglycemia were completely different between the non-DM and DM groups.Fig. 1Flowchart of study participants. *Non-DM* non-diabetes, *DM* diabetes mellitusTable 1Clinical profiles upon arrivalCharacteristicsNon-DM (*n* = 163)DM (*n* = 367)*P* valueAge (years)63.3 ± 20.066.1 ± 16.50.08Women58 (35.6 %)/163120 (32.7 %)/3670.51History of cardiovascular disease18 (11.0 %)/16369 (18.8 %)/3670.02Preexisting disease Hypertension31 (19.0 %)/163223 (60.8 %)/367\<0.001 Atrial fibrillation5 (3.1 %)/16319 (5.2 %)/3670.36 Advanced liver disease7 (4.3 %)/16315 (4.1 %)/367\>0.99 Cancer other than HCC11 (6.8 %)/16311 (3.0 %)/3670.05Blood glucose (mg/dL) (*n* = 529)42.9 ± 23.233.7 ± 15.7\<0.001Creatinine (mg/dL) (*n* = 490)1.06 ± 0.831.36 ± 1.450.01Estimated GFR (mL/min/1.73 m^2^) (*n* = 490)72.6 ± 37.361.6 ± 32.2\<0.001Causes of severe hypoglycemia Glucose-lowering medications3 (1.8 %)/163^a^342 (93.2 %)/367\<0.001 Malnutrition65 (39.9 %)/1634 (1.1 %)/367\<0.001 Alcohol38 (23.3 %)/16310 (2.7 %)/367\<0.001 Post-gastrectomy13 (8.0 %)/1634 (1.1 %)/367\<0.001 Infection14 (8.6 %)/1634 (1.1 %)/367\<0.001 Others30 (18.4 %)/1633 (0.8 %)/367\<0.001Data are represented as the number, number (%)/total number, or mean ± SD. ***N*** *on-DM* non-diabetes, *DM* diabetes mellitus, *HCC* hepatocellular carcinoma, *GFR* glomerular filtration rateInfection was defined as the presence of a bacterial or viral infectious diseaseSI conversion factors: to convert blood glucose to mmol/L, multiply by 0.0555; to convert creatinine to μmol/L, multiply by 88.4History of cardiovascular disease was defined as a history of myocardial infarction, angina pectoris, stroke, or peripheral artery diseaseAdvanced liver disease was defined as the presence of cirrhosis or hepatocellular carcinomaCancer was defined as any cancer excluding fully healed cancerEstimated GFR was calculated using the following formula: estimated GFR (mL/min/1.73 m^2^) = 194 × Cre^−1.094^ × age^−0.287^ (×0.739, if the patient was female)^a^Two patients attempted suicide using insulin, and one patient took sulfonylurea incorrectly. All three patients were safely discharged from the hospital

The clinical conditions and events upon arrival and the mortality in patients with severe hypoglycemia are shown in Table [2](#Tab2){ref-type="table"}. The GCS scores in the non-DM and DM groups were 10.7 ± 4.2 and 10.0 ± 4.1, respectively, and these scores were not significantly different. In each group, the GCS scores of the patients with a blood glucose level \<40 mg/dL were significantly lower than those with a blood glucose level ≥40 mg/dL \[8.4 ± 4.4 vs. 13.0 ± 2.5 in the non-DM group (*P* \< 0.001); 9.0 ± 3.9 vs. 13.0 ± 3.0 in the DM group (*P* \< 0.001)\]. The systolic and diastolic blood pressures were significantly lower in the non-DM group than in the DM group. The incidence of severe hypertension in the DM group was three times as high as that in the non-DM group. The body temperature was significantly lower in the non-DM group than that in the DM group, and the incidence of moderate to severe hypothermia was significantly higher in the non-DM group than in the DM group. The body temperature was significantly lower in patients with a blood glucose level \<40 mg/dL, compared with those with a blood glucose level ≥40 mg/dL \[34.5 ± 2.7 vs. 35.5 ± 2.2 °C in the non-DM group (*P* = 0.01); 35.4 ± 1.0 vs. 36.0 ± 1.0 °C in the DM group (*P* \< 0.001)\]. The serum potassium levels were significantly lower in the DM group than in the non-DM group. The incidence of QT prolongation was high in both groups. Although a QTc ≥0.50 s in the non-DM group was not associated with the blood glucose level and potassium level upon arrival, the body temperature was significantly lower in patients with a QTc ≥0.50 s, compared with those with a QTc \<0.50 s \[32.8 ± 3.2 vs. 35.7 ± 1.5 °C (*P* \< 0.001)\]. Although no significant difference was seen between the groups, the incidence of new-onset cardiovascular disease during an episode of severe hypoglycemia was higher in the DM group than in the non-DM group. The patients with new-onset atrial fibrillation in the non-DM group had a significantly higher incidence of a QTc ≥0.50 s than those without new-onset atrial fibrillation (*P* = 0.04). Fatal arrhythmias upon arrival, such as complete atrioventricular block, ventricular tachycardia, ventricular fibrillation, and torsade de pointes, were not observed in the study patients. The hospitalization rates in the non-DM and DM groups were 54.6 and 27.8 %, respectively, and these were significantly different (*P* ≤ 0.001). The lengths of hospital stay in both groups were not significantly different between patients with a blood glucose level of ≤40 and ≥40 mg/dL \[8 (3--21) days vs. 7 (2--14) days in the non-DM group (*P* = 0.35); 8 (2--19) days vs. 9 (2--20) days in the DM group (*P* = 0.97)\]. In the non-DM group, the mortality rate was 20.3 %, which was more than ten times as high as that in the DM group. The major causes of death in the non-DM group were infection (51.5 %), advanced liver disease (15.2 %), and cancer (9.1 %), while those in the DM group were infection (83.3 %) and advanced liver disease (16.7 %).Table 2Clinical conditions and events upon arrival and mortality in patients with severe hypoglycemiaConditions, events, and mortalityNon-DMDM*P* valueGCS score (*n* = 518)10.7 ± 4.210.0 ± 4.10.07Systolic blood pressure (mmHg) (*n* = 521)126.0 ± 31.1165.6 ± 35.4\<0.001Diastolic blood pressure (mmHg) (*n* = 515)73.2 ± 22.580.2 ± 22.0\<0.001Severe hypertension13 (8.1 %)/160122 (33.6 %)/363\<0.001 Preexisting hypertension (+)3 (9.7 %)/3187 (39.0 %)/2230.001 Preexisting hypertension (−)10 (7.8 %)/12935 (25.0 %)/140\<0.001Body temperature (*n* = 477)35.0 ± 2.535.6 ± 1.0\<0.001 Mild hypothermia45 (29.8 %)/15172 (22.0 %)/3280.06 Moderate or severe hypothermia18 (11.9 %)/1511 (0.3 %)/328\<0.001Serum potassium (mEq/L) (*n* = 503)3.9 ± 0.83.7 ± 0.7\<0.001 \<3.5 mEq/L42 (26.6 %)/158126 (35.7 %)/3530.04QT prolongation (*n* = 95) QTc ≥0.44 s54 (56.8 %)/95108 (58.7 %)/1840.76 QTc ≥0.50 s21 (22.1 %)/9527 (14.7 %)/1840.11Newly diagnosed complications upon arrival Cardiovascular disease1 (0.6 %)/1635 (1.36 %)/3670.67 Atrial fibrillation7 (4.3 %)/16314 (3.8 %)/3670.81Coexisting sepsis29 (17.8 %)/16315 (4.1 %)/367\<0.001Death within 90 days after severe hypoglycemia33 (20.3 %)/1636 (1.6 %)/367\<0.001Data are represented as the mean ± SD or number (%)/total number. *GCS* Glasgow Coma Scale, *DM* diabetes mellitus, *QTc* corrected QT interval calculated using Bazett's formulaSevere hypertension was defined as systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHgPreexisting hypertension was confirmed when the patient was being treated with antihypertensive medication or had been previously diagnosed as having hypertensionMild hypothermia was defined as a body temperature \<35 °C, and moderate to severe hypothermia was defined as \<32 °CSerum potassium levels were measured upon arrivalQTc was calculated using Bazett's formula: QTc = QT interval ÷ square root of the RR intervalCardiovascular disease was defined as coronary heart disease requiring treatment with revascularization or stroke that was confirmed on radiological imagesSepsis was defined as systemic inflammatory response syndrome in response to infection. Systemic inflammatory response syndrome was regarded as the presence of two or more of the following criteria: body temperature \>38 or \<36 °C, heart rate \>90 beats per minute, respiratory rate \>20 breaths per minute, and white blood cell \>12,000 per mm^3^

Analyses of the clinical variables in patients with and those without death in the non-DM group are shown in Table [3](#Tab3){ref-type="table"}. Age, preexisting advanced liver disease and cancer, coexisting sepsis, and the blood glucose level differed significantly between the two groups when examined using univariate analyses. When a Cox proportional hazards regression was used, these five variables were independently associated with death, and a blood glucose level of \<40 mg/dL was one of the strongest predictors (hazard ratio 3.75; 95 % confidence interval 1.52--9.27; *P* = 0.004). Kaplan--Meier survival curves for the patients with blood glucose levels of \<40 and ≥40 mg/dL in the non-DM group are shown in Fig. [2](#Fig2){ref-type="fig"}. Even though causes of severe hypoglycemia such as malnutrition, alcohol, and post-gastrectomy were included in the multivariate analysis, only these five variables were independently associated with death.Table 3Analyses of clinical variables according to death or survival in non-diabetic patients with severe hypoglycemiaVariableHazard ratio95 % CI*P* valueUnivariate analysis Age (years)1.031.01--1.060.003  ≥652.641.14--6.100.02 Women0.810.40--1.630.56 Preexisting diseases  Hypertension1.580.75--3.320.22  Atrial fibrillation1.440.34--6.050.61  Advanced liver disease7.402.79--19.63\<0.001  Cancer2.901.01--8.320.04 QTc ≥0.50 s1.260.33--4.800.72 Coexisting sepsis3.911.96--7.82\<0.001 Blood glucose (mg/dL)0.960.94--0.98\<0.001  \<404.651.91--11.310.001Multivariate analysis Age (years) ≥653.421.33--8.810.01 Advanced liver disease9.683.24--28.86\<0.001 Cancer3.641.22--10.880.02 Sepsis3.171.55--6.480.002 Blood glucose (mg/dL) \<403.751.52--9.270.004Data are represented as the hazard ratio or 95 % CI. To convert blood glucose to mmol/L, multiply by 0.0555Advanced liver disease was defined as the presence of cirrhosis or hepatocellular carcinomaCancer was defined as any cancer excluding hepatocellular carcinoma and fully healed cancerQTc was calculated using Bazett's formula: QTc = QT interval ÷ square root of the RR intervalSepsis was defined as the presence of systemic inflammatory response syndrome in response to infection. Systemic inflammatory response syndrome was regarded as the presence of two or more of the following criteria: body temperature \>38 or \<36 °C, heart rate \>90 beats per minute, respiratory rate \>20 breaths per minute, and white blood cell \>12,000 per mm^3^*CI* confidence intervalFig. 2Kaplan--Meier analysis of the time to death after severe hypoglycemia. *BG* blood glucose

Discussion {#Sec7}
==========

This systematic study is, to the best of our knowledge, the first to report that death in non-diabetic patients with pre-hospital severe hypoglycemia was independently associated not only with age, advanced liver disease, cancer, and sepsis, but also with the blood glucose level upon arrival.

Hypoglycemia leads to the activation of the sympathoadrenal system, and the release of epinephrine and norepinephrine results in hemodynamic changes \[[@CR2], [@CR17], [@CR18]\]. Moreover, profound hypoglycemia causes neuroglycopenic symptoms, including seizure and coma. Many patients with severe hypoglycemia exhibited low consciousness levels, regardless of the presence or absence of diabetes, and the consciousness levels were significantly lower in patients with lower blood glucose levels. Blood pressure during severe hypoglycemia was significantly higher in patients with diabetes than in those without diabetes. Non-diabetic patients with severe hypoglycemia had a broad range of causes for their conditions, such as malnutrition and alcohol abuse, and their illnesses might have led to an insufficient elevation in blood pressure. In addition, previous studies have shown that hypothermia was associated with hypoglycemia \[[@CR2], [@CR19]\]. However, the body temperature of patients with severe hypoglycemia, particularly of non-diabetic patients with severe hypoglycemia, has rarely been examined in clinical settings. This study suggested that mild to severe hypothermia during an episode of severe hypoglycemia was often observed in patients with or without diabetes, and hypothermia was more frequent in patients with lower blood glucose levels than in those with higher blood glucose levels. Although the coexistence of sepsis could lead to hypothermia, thereby influencing the body temperature, intracellular glycopenia at the thermoregulatory center in the hypothalamus might also be one of the central causes of hypothermia \[[@CR19]\]. Because hypothermia can lead to further serious outcomes, including lethal arrhythmias, the association between hypoglycemia and arrhythmias should be investigated. The serum potassium levels in patients with severe hypoglycemia have never been sufficiently clarified. Several factors including blood pH, insulin and catecholamine levels, potassium intake, and renal function might influence the serum potassium levels in patients with severe hypoglycemia. Similar to hypothermia, hypokalemia also increases the risk of lethal arrhythmias.

Several studies have reported an association between hypoglycemia and QT prolongation in patients with diabetes \[[@CR2], [@CR20]--[@CR22]\]. This study demonstrated that not only diabetic patients, but also non-diabetic patients with severe hypoglycemia frequently had an abnormal QT prolongation. Although many causes could lead to acquired long QT syndrome, hypothermia in patients with severe hypoglycemia might be strongly associated with prolonged QT intervals. Because patients with QT prolongation might have torsade de pointes and might have a higher mortality than those without QT prolongation \[[@CR15], [@CR23], [@CR24]\], QT prolongation could be another threat in patients with severe hypoglycemia. In addition, although the association between highly abnormal QT prolongation and new-onset atrial fibrillation in non-diabetic patients with severe hypoglycemia may be supported by a recent study that revealed an association between QT prolongation and the onset of atrial fibrillation \[[@CR25]\], further research is required to confirm an association.

Previous reports have suggested that severe hypoglycemia is associated with increased mortality \[[@CR6]--[@CR8]\]. However, little data are available regarding the outcomes of patients with severe and non-iatrogenic hypoglycemia. Our study showed that non-diabetic patients with severe hypoglycemia frequently died in the absence of glucose-lowering interventions. The characteristics of non-diabetic patients with severe hypoglycemia differed substantially from those of diabetic patients, which might have influenced the patient outcomes. In addition to age, advanced liver disease, cancer, and sepsis, the blood glucose level was independently associated with death in non-diabetic patients with severe hypoglycemia. Severe hypoglycemia in elderly and cancer patients might be one of the important findings for their critical condition. When patients with liver cirrhosis and/or hepatocellular carcinoma develop non-iatrogenic hypoglycemia, gluconeogenesis and glycogenolysis might be severely impaired---suggesting extremely serious liver damage. Meanwhile, hypoglycemia is sometimes complicated by the presence of sepsis \[[@CR26]\]. Although sepsis-induced hypoglycemia might arise from a decrease in glucose production and an increase in glucose uptake by macrophage-rich tissues \[[@CR27], [@CR28]\], the causes remained unclear. However, sepsis with hypoglycemia could be much more serious than those without hypoglycemia \[[@CR10]\]. Additionally, blood glucose is a major energy source in almost all organs and is essential for survival. When blood glucose levels are low in patients with non-iatrogenic hypoglycemia, insulin secretion is promptly suppressed and counter-regulatory hormones, such as glucagon, catecholamines, cortisol, and growth hormone, are secreted in considerable quantities, elevating the blood glucose level. However, when these biological reactions do not lead to an increase in the blood glucose level, the underlying diseases might be extremely severe, and all the organs are likely facing critical situations as a result of the underlying diseases and the hypoglycemic conditions. Although unknown variables might exist, the blood glucose level during episodes of severe hypoglycemia might reflect the severity of the underlying disease. Moreover, non-diabetic patients might not adapt adequately to hypoglycemia compared with diabetic patients. This might be one of the reasons for the higher mortality of patients without diabetes than that of patients with diabetes.

The present study had several limitations. First, missing data \[including acute physiology and chronic health evaluation (APACHE) II scores\] and missing confounding factors might have influenced the results. However, there is no systematic study investigating the detailed conditions and predictors of death in non-diabetic patients with pre-hospital severe hypoglycemia. Therefore, we believe that the present study supplies very important information about severe hypoglycemia in clinical settings. Second, this study was performed at a single national center, and the study patients were from a specific geographical area. Further research at multiple centers throughout the world is needed. Third, patients with pre-hospital cardiopulmonary arrest could not be examined. Some patients with severe hypoglycemia might have died from cardiovascular events, lethal arrhythmias, or other critical events in pre-hospital settings. Nevertheless, we believe that our study provides novel information about severe hypoglycemia.

Conclusion {#Sec8}
==========

The present study revealed that in addition to patient age, preexisting advanced liver disease, cancer, and coexisting sepsis, the blood glucose level was one of the strongest predictors of death after an episode of severe hypoglycemia in non-diabetic patients. Mortality of non-diabetic patients with pre-hospital severe hypoglycemia was extremely high, and more attention should be paid to their blood glucose levels.
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